ClinicalTrials.gov
public full text
Public Domain
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies
The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or receiving another disease-modifying therapy, is to further explore the incidence of selected safety- related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One#1104324
- Summary of Research: Cognition and Employment Status of People with Relapsing Multiple Sclerosis Treated with Cladribine Tablets: Two-Year CLARIFY-MS Study#642355
- Efficacy of Diet on Quality of Life in Multiple Sclerosis#825478
- Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis#868205
- Validity and Reliability of Timed Up and Go Test in Dual-Task Conditions for Multiple Sclerosis Patients#842651
Record · ID 877602
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive